Sandu Pharma.

Market Cap: Micro Cap
Industry: Trading
ISIN: INE751D01014
NSEID:
BSEID: 524703

INR

49.48

1.49 (3.1%)

BSENSE

Apr 11, 12:50 PM

BSE+NSE Vol: 1.2 k

{
  "main_header": {
    "sid": 764862,
    "name": "Sandu Pharma.",
    "stock_name": "Sandu Pharma.",
    "full_name": "Sandu Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/sandu-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "49.48",
    "chg": 1.49,
    "chgp": "3.1%",
    "dir": 1,
    "prev_price": "47.99",
    "mcapval": "46.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524703,
    "symbol": "",
    "ind_name": "Trading",
    "ind_code": 49,
    "isin": "INE751D01014",
    "curr_date": "Apr 11, 12:50 PM",
    "curr_time": "01:19 AM",
    "bse_nse_vol": "1.2 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sandu-pharma-764862-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Sandu Pharmaceuticals Adjusts Valuation Amidst Competitive Market Landscape Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-valuation-grade-changes-from-expensive-to-fair-amid-price-decline-1636858",
        "imagepath": "",
        "date": "2025-03-28 08:00:33",
        "description": "Sandu Pharmaceuticals has recently undergone a valuation adjustment, reflecting its current market position within the trading industry. The company's price-to-earnings ratio stands at 30.38, while its price-to-book value is recorded at 1.09. Other key financial metrics include an EV to EBIT ratio of 23.65 and an EV to EBITDA ratio of 17.22, indicating its operational efficiency relative to its enterprise value.\n\nIn terms of returns, Sandu Pharmaceuticals has faced challenges, with a year-to-date decline of 19.26%, contrasting with a slight decrease in the Sensex of 0.68% during the same period. Over the past year, the stock has dropped by 19.81%, while the Sensex has gained 6.32%. However, the company has shown resilience over a longer horizon, with a five-year return of 303.76%, significantly outperforming the Sensex's 160.29% increase.\n\nWhen compared to its peers, Sandu Pharmaceuticals presents a mixed p..."
      },
      {
        "title": "Sandu Pharmaceuticals Faces Increased Volatility Amid Weak Performance Metrics and Market Trends",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-hits-52-week-low-amid-continued-stock-decline-and-high-volatility-1628496",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/SanduPharmaceut_priceRelatedfactors_826351.png",
        "date": "2025-03-27 14:36:33",
        "description": "Sandu Pharmaceuticals has faced notable volatility, reaching a new 52-week low and experiencing a significant decline over the past four days. The company's one-year performance shows a substantial drop, contrasting with broader market gains, while its fundamentals indicate a weak long-term outlook and challenges in servicing debt."
      },
      {
        "title": "Sandu Pharmaceuticals Adjusts Valuation Grade Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-valuation-grade-downgraded-from-very-expensive-to-expensive-6-1542089",
        "imagepath": "",
        "date": "2025-03-21 08:00:34",
        "description": "Sandu Pharmaceuticals has recently undergone a valuation adjustment, reflecting its current market position within the trading industry. The company's price-to-earnings ratio stands at 33.52, while its price-to-book value is recorded at 1.21. Other key financial metrics include an EV to EBIT ratio of 26.25 and an EV to EBITDA ratio of 19.12, indicating its operational efficiency relative to its enterprise value.\n\nIn terms of profitability, Sandu Pharmaceuticals has a return on capital employed (ROCE) of 4.65% and a return on equity (ROE) of 3.60%. The company also offers a dividend yield of 1.57%, which may appeal to certain investors looking for income generation.\n\nWhen compared to its peers, Sandu Pharmaceuticals presents a higher valuation in terms of its price-to-earnings ratio than several competitors, such as Kamdhenu and Sat Industries, which have lower ratios. However, it is positioned more favorabl..."
      },
      {
        "title": "Sandu Pharmaceuticals Faces Ongoing Challenges Amid Significant Stock Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-hits-52-week-low-as-stock-declines-12-54-over-three-days-1173012",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/SanduPharmaceut_priceRelatedfactors_562607.png",
        "date": "2025-03-03 10:36:25",
        "description": "Sandu Pharmaceuticals has faced significant volatility, hitting a new 52-week low of Rs. 47 and experiencing a total decline of 12.54% over the past three days. The stock has underperformed its sector and is trading below key moving averages, indicating ongoing challenges in the market."
      },
      {
        "title": "Sandu Pharmaceuticals Faces Significant Volatility Amidst Ongoing Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-hits-52-week-low-amid-continued-stock-decline-1141332",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/SanduPharmaceut_priceRelatedfactors_549191.png",
        "date": "2025-02-28 10:35:34",
        "description": "Sandu Pharmaceuticals has faced significant volatility, hitting a new 52-week low of Rs. 48.03 amid a broader decline of 10.63% over two days. The stock is trading below all major moving averages and has decreased by 28.93% over the past year, contrasting with the Sensex's gains."
      },
      {
        "title": "Sandu Pharmaceuticals Hits 52-Week Low Amid Ongoing Market Struggles",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-hits-new-52-week-low-at-rs-48-5-amid-significant-decline-1130606",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/SanduPharmaceut_priceRelatedfactors_533166.png",
        "date": "2025-02-27 12:05:22",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low of Rs. 48.5, reflecting a significant decline and underperformance compared to its sector. The stock is trading below all major moving averages and has decreased by 28.28% over the past year, amidst broader sector challenges."
      },
      {
        "title": "Sandu Pharmaceuticals Adjusts Valuation Amid Mixed Sector Performance and Competitive Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-valuation-grade-downgraded-from-very-expensive-to-expensive-1109303",
        "imagepath": "",
        "date": "2025-02-25 10:23:21",
        "description": "Sandu Pharmaceuticals, a microcap player in the trading industry, has recently undergone a valuation adjustment. The company's current price stands at 52.54, slightly above its previous close of 52.50. Over the past year, Sandu has experienced a stock return of -27.22%, contrasting with a modest gain of 2.06% in the Sensex during the same period. \n\nKey financial metrics reveal a PE ratio of 34.50 and an EV to EBITDA ratio of 19.72, indicating a competitive position within its sector. The PEG ratio is noted at 0.58, suggesting a potentially favorable growth outlook relative to its earnings. Additionally, the company boasts a dividend yield of 1.52%, which may appeal to certain investors.\n\nWhen compared to its peers, Sandu Pharmaceuticals presents a mixed picture. While it maintains a higher PE ratio than some competitors, others in the industry, such as Kamdhenu and Zuari Industries, exhibit lower valuations..."
      },
      {
        "title": "Sandu Pharmaceuticals Hits 52-Week Low Amid Ongoing Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-hits-52-week-low-at-rs-50-04-amid-ongoing-decline-991162",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/SanduPharmaceut_priceRelatedfactors_418309.png",
        "date": "2025-02-12 10:06:32",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low, reflecting a significant decline in its stock performance. The company has underperformed its sector and experienced a consecutive drop over the past four days. Additionally, it is trading below multiple moving averages, indicating a bearish trend amid broader market challenges."
      },
      {
        "title": "Sandu Pharmaceuticals Hits 52-Week Low Amid Broader Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-hits-52-week-low-at-rs-50-1-amid-28-72-annual-decline-350893",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/1/SanduPharmaceut_priceRelatedfactors_261896.png",
        "date": "2025-01-28 10:35:42",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low, reflecting a significant decline in its stock price over the past two days. The company is trading below all key moving averages, with a notable year-over-year drop, contrasting with the overall market's positive performance. This indicates ongoing challenges for the firm."
      }
    ],
    "total": 20,
    "sid": "764862",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/sandu-pharmaceuticals-764862"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "05-Apr-2025",
      "details": "Certificate under Regulation 74(5) of SEBI (DP) Regulation 2018",
      "source": "BSE"
    },
    {
      "caption": "Disclosure In Terms Of Regulation 31(4) Of The SEBI (Substantial Acquisition Of Shares And Takeover) Regulations 2011",
      "datetime": "03-Apr-2025",
      "details": "Disclosure in term of regulation 31(4) of the SEBI (SAST) Regulation 2011",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "24-Mar-2025",
      "details": "intimation about closure of trading window for approval of audited financial results for q and year ended 31.03.2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sandu Pharmaceuticals Ltd has declared <strong>8%</strong> dividend, ex-date: 19 Sep 24",
          "dt": "2024-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Sandu Pharmaceuticals Adjusts Valuation Amidst Competitive Market Landscape Challenges

2025-03-28 08:00:33

Sandu Pharmaceuticals has recently undergone a valuation adjustment, reflecting its current market position within the trading industry. The company's price-to-earnings ratio stands at 30.38, while its price-to-book value is recorded at 1.09. Other key financial metrics include an EV to EBIT ratio of 23.65 and an EV to EBITDA ratio of 17.22, indicating its operational efficiency relative to its enterprise value. In terms of returns, Sandu Pharmaceuticals has faced challenges, with a year-to-date decline of 19.26%, contrasting with a slight decrease in the Sensex of 0.68% during the same period. Over the past year, the stock has dropped by 19.81%, while the Sensex has gained 6.32%. However, the company has shown resilience over a longer horizon, with a five-year return of 303.76%, significantly outperforming the Sensex's 160.29% increase. When compared to its peers, Sandu Pharmaceuticals presents a mixed p...

Sandu Pharmaceuticals Faces Increased Volatility Amid Weak Performance Metrics and Market Trends

2025-03-27 14:36:33

Sandu Pharmaceuticals has faced notable volatility, reaching a new 52-week low and experiencing a significant decline over the past four days. The company's one-year performance shows a substantial drop, contrasting with broader market gains, while its fundamentals indicate a weak long-term outlook and challenges in servicing debt.

Sandu Pharmaceuticals Adjusts Valuation Grade Amid Competitive Market Landscape

2025-03-21 08:00:34

Sandu Pharmaceuticals has recently undergone a valuation adjustment, reflecting its current market position within the trading industry. The company's price-to-earnings ratio stands at 33.52, while its price-to-book value is recorded at 1.21. Other key financial metrics include an EV to EBIT ratio of 26.25 and an EV to EBITDA ratio of 19.12, indicating its operational efficiency relative to its enterprise value. In terms of profitability, Sandu Pharmaceuticals has a return on capital employed (ROCE) of 4.65% and a return on equity (ROE) of 3.60%. The company also offers a dividend yield of 1.57%, which may appeal to certain investors looking for income generation. When compared to its peers, Sandu Pharmaceuticals presents a higher valuation in terms of its price-to-earnings ratio than several competitors, such as Kamdhenu and Sat Industries, which have lower ratios. However, it is positioned more favorabl...

Sandu Pharmaceuticals Faces Ongoing Challenges Amid Significant Stock Volatility

2025-03-03 10:36:25

Sandu Pharmaceuticals has faced significant volatility, hitting a new 52-week low of Rs. 47 and experiencing a total decline of 12.54% over the past three days. The stock has underperformed its sector and is trading below key moving averages, indicating ongoing challenges in the market.

Sandu Pharmaceuticals Faces Significant Volatility Amidst Ongoing Market Challenges

2025-02-28 10:35:34

Sandu Pharmaceuticals has faced significant volatility, hitting a new 52-week low of Rs. 48.03 amid a broader decline of 10.63% over two days. The stock is trading below all major moving averages and has decreased by 28.93% over the past year, contrasting with the Sensex's gains.

Sandu Pharmaceuticals Hits 52-Week Low Amid Ongoing Market Struggles

2025-02-27 12:05:22

Sandu Pharmaceuticals has reached a new 52-week low of Rs. 48.5, reflecting a significant decline and underperformance compared to its sector. The stock is trading below all major moving averages and has decreased by 28.28% over the past year, amidst broader sector challenges.

Sandu Pharmaceuticals Adjusts Valuation Amid Mixed Sector Performance and Competitive Metrics

2025-02-25 10:23:21

Sandu Pharmaceuticals, a microcap player in the trading industry, has recently undergone a valuation adjustment. The company's current price stands at 52.54, slightly above its previous close of 52.50. Over the past year, Sandu has experienced a stock return of -27.22%, contrasting with a modest gain of 2.06% in the Sensex during the same period. Key financial metrics reveal a PE ratio of 34.50 and an EV to EBITDA ratio of 19.72, indicating a competitive position within its sector. The PEG ratio is noted at 0.58, suggesting a potentially favorable growth outlook relative to its earnings. Additionally, the company boasts a dividend yield of 1.52%, which may appeal to certain investors. When compared to its peers, Sandu Pharmaceuticals presents a mixed picture. While it maintains a higher PE ratio than some competitors, others in the industry, such as Kamdhenu and Zuari Industries, exhibit lower valuations...

Sandu Pharmaceuticals Hits 52-Week Low Amid Ongoing Sector Challenges

2025-02-12 10:06:32

Sandu Pharmaceuticals has reached a new 52-week low, reflecting a significant decline in its stock performance. The company has underperformed its sector and experienced a consecutive drop over the past four days. Additionally, it is trading below multiple moving averages, indicating a bearish trend amid broader market challenges.

Sandu Pharmaceuticals Hits 52-Week Low Amid Broader Sector Challenges

2025-01-28 10:35:42

Sandu Pharmaceuticals has reached a new 52-week low, reflecting a significant decline in its stock price over the past two days. The company is trading below all key moving averages, with a notable year-over-year drop, contrasting with the overall market's positive performance. This indicates ongoing challenges for the firm.